The Current Landscape in the Management of Chronic Liver Disease

Release Date: 2/20/2015
Expiration Date: 2/20/2016

Estimated Time to Complete Activity: 4.0 hours

Complications of Cirrhosis

Ira Jacobson, MD

Professor of Medicine, The Joan Sanford I. Weill Medical College of Cornell University
New York, NY

Differential Diagnosis

Hillel Tobias, MD, PhD

New York University Medical Center
New York, NY

Screening/Natural History/Staging of HCV

Course Director

Douglas Dieterich, MD

Professor of Medicine and Liver Disease
Icahn School of Medicine at Mount Sinai
New York, NY

Present HCV Treatments

David Bernstein, MD

Professor, Hofstra North Shore-LIJ School of Medicine
Roslyn, NY

Future HCV Treatments

Ira Jacobson, MD

Professor of Medicine, The Joan Sanford I. Weill Medical College of Cornell University
New York, NY

Q & A

Target Audience - The educational initiative is intended for physicians, allied professionals, residents, fellows, and students from the specialties that we anticipate will be screening for, referring, and treating HCV and liver disease.

Statement of Need - The purpose of the activity to provide strategies to prevent disease, educate health care providers about the disease, increase disease surveillance, and improve the therapeutic management and patient outcomes.

Learning Objectives

Demonstrate knowledge of evaluation of liver disease and the benefits of linkage to care through a multi-specialty approach, which is aimed at improving performance in practice

Define and recognize appropriate management for HCV and liver disease treatment

Apply knowledge regarding advances in the effective and safe treatment and management
of HCV

Compare different medications and formulate treatment plans based on known effectiveness
of the therapies

Accreditation Statement - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Icahn School of Medicine at Mount Sinai and the Empire Liver Foundation (ELF). The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement -The Icahn School of Medicine at Mount Sinai designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Dr. David Bernstein is an advisory board member for Gilead, AbbVie, Janssen and Merck. He has received Grants/Research support from Gilead, AbbVie, Janssen and Merck. He is a Consultant/Speaker for Gilead, AbbVie, Janssen and Merck. He is an honorarium recipient from Gilead, AbbVie, Janssen and Merck.

Dr. Douglas Dieterich is a Consultant/Advisor for Boehringer Ingelheim, Bristol-Myers Squibb and Gilead. He has received compensation for consulting fees, honoraria and as an advisory board member from Boehringer Ingelheim, Bristol-Myers Squibb and Gilead.

Dr. Ira Jacobson is a consultant/ Advisor for Abbvie, Achillion, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Idenix, Genentech, Merck, Janssen, and Vertex. He is a grant recipient from Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Novartis, Genentech, Merck, Janssen, and Vertex. Dr. Jacobson is a speaker bureau member for Bristol Myers Squibb, Gilead, Genentech, Vertex, and Janssen.

Dr. Hillel Tobias, MD is a consultant/advisor for Abbvie, Bristol-Myers Squibb, Gilead, Janssen and Merck. Dr Tobias has received honoraria for lectures, papers or teaching from AbbVie, Bristol-Myers Squibb, Gilead, Janssen and Merck. Dr. Tobias has received compensation for service on advisory boards from AbbVie, Bristol-Myers Squibb, Gilead, Janssen and Merck.

Peer Reviewed by: Linda Law, MD
Assistant Professor Medicine, Liver Diseases
Icahn School of Medicine at Mount Sinai
No financial relationships to disclose.

Medium There are no fees for participating in or receiving credit for this online activity.

Method of Participation To receive a maximum of 4.0 AMA PRA Category 1 Credit(s) ™
you should:

Review the activity objectives and CME information

View the presentations in this enduring material

All webcasts must be viewed in their entirety in order to receive full credit

Complete the posttest and activity evaluation form

A score of at least 70% is required to successfully complete this activity and receive CME credit

Hardware/software requirements Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

Privacy and Confidentiality Policy The Icahn School of Medicine protects the privacy of personal and other information regarding participants and educational collaborations. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

Disclaimer – The information provided in this webcast is for continuing education purposes only. The content is not meant to provide medical judgment, diagnostic or treatment options for any medical condition. Use of this information is not suitable outside the scope of this activity.

Contact Information: For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity at cme@mssm.edu. For technical assistance, contact jranagan@focusmeded.com.

Copyright - This material is protected by copyright and other intellectual property laws. It may not be otherwise copied, printed, transmitted, or published unless explicit permission is obtained. To request permission, please contact us at info@focusmeded.com.

Commercial Support - This activity is supported from independent educational grants from AbbVie, Bristol-Myers Squibb, Gilead and Janssen Therapeutics.

 

Jointly provided by